Cargando…

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer

Background: EGFR expression and pathway activation are common in triple-negative breast cancer (TNBC). However, anti-EGFR therapies have not been effective in these patients. We aimed to study the efficacy of targeting MET in overcoming resistance to EGFR therapy in TNBC cell lines. Methods: TNBC li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Joohyuk, Liu, Shuying, Parinyanitikul, Napa, Lee, Jangsoon, Hortobagyi, Gabriel N., Mills, Gordon B., Ueno, Naoto T., Gonzalez-Angulo, Ana M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216798/ https://www.ncbi.nlm.nih.gov/pubmed/25368674 http://dx.doi.org/10.7150/jca.9696

Ejemplares similares

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer
por: Chae, Young Kwang, et al.
Publicado: (2016)

Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

The Role of cMET in Gastric Cancer—A Review of the Literature
por: Van Herpe, Filip, et al.
Publicado: (2023)

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor
por: Sakr, Hany I, et al.
Publicado: (2015)

Urinary cMet as a prognostic marker in immunoglobulin A nephropathy
por: An, Jung Nam, et al.
Publicado: (2020)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors
por: Collie, Gavin W., et al.
Publicado: (2019)

Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis
por: Kim, Yong Chul, et al.
Publicado: (2019)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
por: Ohara, Masahiro, et al.
Publicado: (2021)

The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
por: Armstrong, Gemma R., et al.
Publicado: (2021)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018)

cMet agonistic antibody attenuates apoptosis in ischaemia‐reperfusion–induced kidney injury
por: An, Jung Nam, et al.
Publicado: (2020)

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
por: Wu, D-W, et al.
Publicado: (2016)

Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene
por: Niyomnaitham, Suvimol, et al.
Publicado: (2019)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
por: Van Der Steen, Nele, et al.
Publicado: (2015)

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
por: Singh, Ratnakar, et al.
Publicado: (2019)

Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
por: Wu, Xiaoli, et al.
Publicado: (2019)

EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming
por: Meng, Fanyan, et al.
Publicado: (2019)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

Dual inhibition of RNAi therapeutic miR-26a-5p targeting cMet and immunotherapy against EGFR in endometrial cancer treatment
por: Liu, Yun, et al.
Publicado: (2021)

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Lactic acidosis, a potential toxicity from drug–drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report
por: Lagampan, Chalita, et al.
Publicado: (2021)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
por: Shah, Payal D., et al.
Publicado: (2023)

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
por: Vengoji, Raghupathy, et al.
Publicado: (2019)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

cMetS Based on Z-Scores as an Accurate and Efficient Scoring System to Determine Metabolic Syndrome in Spanish Adolescents
por: Fernández-Aparicio, Ángel, et al.
Publicado: (2022)

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
por: Brandes, Franziska, et al.
Publicado: (2015)

Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
por: Chen, Xiangheng, et al.
Publicado: (2018)

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells
por: Majidi Zolbanin, Naime, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eqtqg2tt3vut3oet7n5qoel111